Clarity Pharmaceuticals (ASX:CU6) said a prospective, investigator-initiated, phase 2 imaging trial seeking to compare the detection rate of sites of prostate cancer recurrence as determined by the number of lesions per patient, between two agents, completed enrollment, and all participants were imaged, according to a Thursday Australian bourse filing.
The study is evaluating the performance of copper-64 SAR-bisPSMA in comparison with the standard-of-care gallium-68-PSMA-11 for the detection of prostate cancer recurrence in patients with low prostate-specific antigen (PSA), who are candidates for curative salvage therapy.
Eligible patients were required to have had a radical prostatectomy with no salvage therapy and a PSA of between 0.2 nanograms per milliliter and 0.75 ng/mL.
The drugmaker's shares rose past 3% in recent trading on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。